Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) saw unusually-high trading volume on Monday . Approximately 287,221 shares changed hands during mid-day trading, a decline of 1% from the previous session’s volume of 290,680 shares.The stock last traded at $5.24 and had previously closed at $4.86.

ARGS has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Monday, August 15th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Argos Therapeutics in a research report on Friday, June 17th. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $11.50.

The stock’s market cap is $215.04 million. The company’s 50 day moving average price is $5.30 and its 200 day moving average price is $5.92.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. On average, equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.49) EPS for the current fiscal year.

In related news, major shareholder International S. Pharmstandard acquired 67,371 shares of the company’s stock in a transaction that occurred on Wednesday, August 24th. The shares were acquired at an average price of $4.52 per share, with a total value of $304,516.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder International S. Pharmstandard acquired 75,474 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The shares were bought at an average cost of $4.24 per share, for a total transaction of $320,009.76. The disclosure for this purchase can be found here.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.